A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Public ClinicalTrials.gov record NCT04640623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Study identification
- NCT ID
- NCT04640623
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2020 (Actual)
- Primary completion
- Jul 3, 2025 (Actual)
- Completion
- Sep 30, 2027 (Estimated)
- Last update posted
- Sep 25, 2026
2020 – 2027
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Del Sol Research Management, LLC | Tucson | Arizona | 85715 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Genesis Healthcare Partners - Genesis Research Greater Los Angeles | Sherman Oaks | California | 91411 | — |
| The Urology Center of Colorado | Denver | Colorado | 80211 | — |
| Foothills Urology - Golden Off | Golden | Colorado | 80401 | — |
| DuPage Medical Group | Lisle | Illinois | 60532 | — |
| Urology of Indiana | Greenwood | Indiana | 46143 | — |
| Wichita Urology Group | Wichita | Kansas | 67226 | — |
| Michigan Institute of Urology | Troy | Michigan | 48084 | — |
| NYU Langone Health | New York | New York | 10017 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210-2375 | — |
| Associated Medical Professionals | Syracuse | New York | 13210 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| The Urology Group | Cincinnati | Ohio | 45212 | — |
| Urologic Consultants of Southeastern Pennsylvania | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Urology Associates, PC | Nashville | Tennessee | 37209 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Urology Austin | Austin | Texas | 78745 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Urology San Antonio Research | San Antonio | Texas | 78229 | — |
| Spokane Urology | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04640623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04640623 live on ClinicalTrials.gov.